The expanded efficacy data across both obstructive and non-obstructive HCM strengthens the case for aficamten as a potential standard-of-care for the full HCM spectrum, with the nHCM sNDA submission expected Q4 2026. Traders should watch for FDA acceptance and priority review designation. CYTK has a $10.8B market cap with 89% analyst buy ratings — consensus is already bullish, so a high-impact approval may already be partially priced in.
Price Chart
Executive Summary
Cytokinetics presented positive additional Phase 3 results at ESC 2026 showing aficamten (MYQORZO) improves cardiac structure and diastolic function in non-obstructive HCM and outperforms metoprolol across pre-trial treatment groups in obstructive HCM. The company plans to submit a supplemental NDA for the nHCM indication in Q4 2026, expanding the drug's potential addressable market beyond the currently approved oHCM population.
Key Facts
- Additional ACACIA-HCM results showed aficamten significantly improved diastolic function (peak E velocity, septal e' velocity) and reduced left ventricular wall thickness (-0.2 cm, p<0.001) in nHCM at up to 72 weeks.
- MAPLE-HCM post-hoc analysis showed aficamten improved pVO2 vs metoprolol irrespective of prior beta-blocker use (no beta blockers: +3.1 mL/kg/min, p<0.001; on beta blockers: +1.9 mL/kg/min, p<0.001).
- Cytokinetics plans to submit a Supplemental New Drug Application for aficamten in non-obstructive HCM in Q4 2026.
Financial Impact
Expansion of aficamten's addressable market to ~50% of HCM patients (nHCM) who currently have no approved therapies; sNDA submission Q4 2026
Risk Factors
- FDA could issue a Complete Response Letter or require additional trials for nHCM, delaying or denying approval.
- Competition from existing therapies (mavacamten/camzyos) and other emerging HCM drugs could limit market share.
- Historical calibration shows prior CYTK reports have poor T+20 performance (30% win rate, avg -1.14%), suggesting the stock may already reflect much of this positive data.
- Aficamten's boxed warning for heart failure risk and REMS program may limit uptake in broader nHCM population.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3352934 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $69.31 $67.59 | ▲ +2.48% | ▲ +4.59% | $65.60 (+5.35%) |
Sep 11, 2026 20d ago | Insider Cluster | $72.45 $67.56 | ▼ −6.75% | ▼ −6.86% | $65.60 (−9.45%) |
Sep 1, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 31, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 29, 2026 4w ago | Press Release | $70.91 $75.35 | ▲ +6.26% | ▲ +6.40% | $65.60 (−7.49%) |
Aug 28, 2026 5w ago | 8-K | $72.09 $72.72 | ▲ +0.87% | ▲ +0.76% | $65.60 (−9.00%) |
Jul 30, 2026 9w ago | Insider Cluster | $80.42 $81.37 | ▲ +1.18% | ▼ −2.44% | $65.60 (−18.43%) |
Jul 27, 2026 9w ago | Insider Cluster | $80.62 $77.13 | ▼ −4.33% | ▼ −5.40% | $65.60 (−18.63%) |
Jul 23, 2026 10w ago | Press Release | $80.74 $80.42 | ▼ −0.40% | ▼ −0.77% | $65.60 (−18.75%) |
Jul 14, 2026 11w ago | Insider Cluster | $81.93 $79.11 | ▼ −3.44% | ▼ −2.15% | $65.60 (−19.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access